RTW Biotech Opportunities Ltd (RTW) Earnings Call Transcripts

RTW Biotech Opportunities Ltd's Latest Earnings Call - March 30, 2026

In the fiscal year ending December 2025, RTW Biotech Opportunities Ltd reported a notable 36% increase in NAV per share, signaling a strong recovery from the previous four-year bear market in biotech. The company highlighted its ability to outperform key indices, with a 23% annualized net return since inception, significantly surpassing the Russell 2000 Biotech Index and the NASDAQ Biotech Index. Management expressed optimism about the future, citing improved market conditions and a wave of maturing innovation in the sector, while the discount to NAV decreased from 23% to 12%.

Reported metrics

Guidance from management

Management indicated that they expect continued strong performance in 2026, driven by a recovering market and a wave of innovation in biotech. They maintained a positive outlook on the IPO market, suggesting it could see significant activity this year.

What management said

So Rod, moving to the questions. Question one, is the alpha opportunity as good in commercial stage companies as clinical stage? Has there been any change to your underwriting targets or the duration of your investments?

Yes. Before the war broke out, this was on track to be the first normal IPO year in several. We remain optimistic, but I think, obviously, the big unknown is how long the Iran war lasts and whether it escalates because that obviously would have some impact on the pace of IPOs, but we're optimistic.

What analysts pressed on

Analysts expressed concerns regarding the potential impact of FDA leadership changes on drug approvals, particularly for rare diseases and gene therapies. There were also questions about whether the recent market recovery is sustainable and how long it might last.

Main topics on the call

• Strong NAV Growth — RTW's NAV per share grew by approximately 36% in 2025, outperforming the NASDAQ Biotech Index and aligning closely with the Russell 2000 Biotech Index. Management stated, "2025 was a great year for RTW Bio and for biotec...
• Market Recovery — The company noted that the latter part of 2025 marked the end of a four-year bear market for biotech, with public equities responding positively. Management indicated that "biotech outperformed broader equity markets" fo...
• Investment Strategy — RTW emphasized its full life cycle investment strategy, which has allowed it to capture significant value across public and private investments. They noted, "We believe strongly that full life cycle investing is really v...
• M&A Activity — The management highlighted a surge in M&A activity, stating that 2025 matched the highest year for $1 billion-plus acquisitions in biotech history. They noted, "Deals accelerate, especially in the fall as U.S. policy ris...

Read the full RTW Biotech Opportunities Ltd transcript (March 30, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 2 RTW Biotech Opportunities Ltd earnings call transcripts on record, spanning September 15, 2022 to March 30, 2026. The most recent call on file is dated March 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

RTW

Exchange

LSE

Country

GB

Sector

Financials

Industry

Capital Markets

Calls on record

2

First call

September 15, 2022

Most recent

March 30, 2026